Drugs & Targets FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer June 23, 2023Vol.49 No.25
An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.” June 16, 2023Vol.49 No.24By Paul Goldberg
Drugs & Targets FDA grants priority review to capivasertib + Faslodex for advanced HR-positive breast cancer June 16, 2023Vol.49 No.24
Drugs & Targets FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC June 02, 2023Vol.49 No.22
Conversation with The Cancer LetterFree Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it May 30, 2023Vol.49 No.22By Paul Goldberg
Drugs & Targets FDA grants accelerated approval to Epkinly for R/R DLBCL and high-grade B-cell lymphoma May 26, 2023Vol.49 No.21
Drugs & Targets FDA grants PYX-201 Orphan Drug Designation in pancreatic cancer May 12, 2023Vol.49 No.19
Regulatory News ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor May 05, 2023Vol.49 No.18By Paul Goldberg
